BioSpace News Archive

SkinCure Oncology presented to dermatology patients as the GentleCure™ Experience, is exhibiting at the American Academy of Dermatology annual meeting in San Diego March 8-12, and unveiling a groundbreaking new technology for the noninvasive treatment of common skin cancers.

Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated to complete its PromethION product range.

Medline, a market-leading manufacturer and supplier of medical supplies and solutions, announced the successful acquisition of the manufacturing rights and intellectual property of AG Cuffill from Hospitech Respiration Ltd.

Vaxxinity, Inc. announced positive clinical data from its UB-312 program in Parkinson’s disease presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease, held virtually and in Lisbon, Portugal from March 5 to March 9, 2024.

Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives, announced that it will release its 2024 first quarter financial results at approximately 6 a.m. ET on Friday, April 26, 2024, and host a conference call at 8:30 a.m. ET to review the results.

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that it has lifted the previously disclosed1 voluntary pause on screening and randomization of its NATiV3 clinical trial and that sites are resuming screening activities.

Adagene Inc. announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board.

Neurona Therapeutics announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy, will be presented at the American Academy of Neurology 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, announced that it has granted as of March 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended.

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) today hosted an investor event highlighting neffy® (epinephrine nasal spray), an investigational new drug, for the treatment of Type I allergic reactions.